# Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

> **NCT06680752** · PHASE1,PHASE2 · RECRUITING · sponsor: **ARCE Therapeutics, Inc.** · enrollment: 49 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- MDS (Myelodysplastic Syndrome)

## Interventions

- **BIOLOGICAL:** ARD103
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06680752
- **Lead sponsor:** ARCE Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-20
- **Primary completion:** 2028-10
- **Final completion:** 2028-12
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680752, "Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06680752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*